What are the Recent Advances in Targeting Mutant KRAS?
Recent advances have provided new hope in targeting mutant KRAS. The development of KRAS G12C inhibitors, such as sotorasib and adagrasib, has shown promising results in clinical trials. These inhibitors specifically target the G12C mutant form of KRAS, locking it in an inactive state. Additionally, researchers are exploring combination therapies that target multiple nodes in the KRAS signaling network to overcome redundancy and resistance mechanisms.
